Related Experiment Videos
Dietary erucic acid therapy for X-linked adrenoleukodystrophy
W B Rizzo1, R T Leshner, A Odone
1Department of Pediatrics, Medical College of Virginia, Virginia Commonwealth University, Richmond.
Neurology
|November 1, 1989
Summary
Dietary erucic acid therapy effectively lowers very long-chain fatty acids in X-linked adrenoleukodystrophy (ALD). This treatment may stabilize neurological symptoms and prevent further demyelination in mildly affected boys.
Area of Science:
- Biochemistry
- Neurology
- Genetics
Background:
- X-linked adrenoleukodystrophy (ALD) is a rare genetic disorder characterized by the accumulation of very long-chain fatty acids (VLCFAs), particularly hexacosanoic acid (C26:0).
- Elevated C26:0 levels lead to inflammation and demyelination, primarily affecting the adrenal glands and central nervous system.
- Current therapies aim to manage symptoms and slow disease progression, but effective biochemical interventions are crucial.
Purpose of the Study:
- To evaluate the biochemical and clinical efficacy of dietary erucic acid (C22:1) therapy in patients with X-linked adrenoleukodystrophy (ALD).
- To assess the impact of erucic acid supplementation on plasma C26:0 concentrations and its distribution in tissues.
- To determine the clinical outcomes and safety of erucic acid therapy in ALD patients.
Main Methods:
- A double-blind crossover study involving patients on chronic oleic acid (C18:1) therapy was conducted.
- Twelve newly diagnosed ALD patients received a diet enriched with erucic acid and oleic acid for 2 to 19 months.
- Plasma C26:0 concentrations and composition in sphingomyelin and phosphatidylcholine were analyzed. Postmortem tissue analysis was performed on one patient.
Main Results:
- Dietary erucic acid further reduced plasma C26:0 concentrations in patients already on oleic acid therapy.
- Mean plasma C26:0 normalized within 4 weeks, and its composition in plasma lipids normalized within 4 months.
- Postmortem tissue analysis indicated erucic acid distribution to key organs, including the brain.
- While 2 mildly affected patients remained clinically stable for 10 and 19 months, 6 patients with moderate to advanced disease showed neurological deterioration or white matter progression.
Conclusions:
- Dietary erucic acid therapy is effective in normalizing plasma C26:0 levels in ALD patients.
- The therapy may prevent further demyelination and stabilize clinical symptoms in a subset of mildly affected boys.
- No adverse effects were observed during the study period, suggesting a favorable safety profile.